非糖尿病肥胖症患者的 GPL-1 药物覆盖范围：事实、虚构和各类计划发起人的潜在成本.pdf

《非糖尿病肥胖症患者的 GPL-1 药物覆盖范围：事实、虚构和各类计划发起人的潜在成本.pdf》由会员分享，可在线阅读，更多相关《非糖尿病肥胖症患者的 GPL-1 药物覆盖范围：事实、虚构和各类计划发起人的潜在成本.pdf（15页珍藏版）》请在三个皮匠报告上搜索。

1、GLP-1 Drug Studies:Efficacy,Endurance,and Cost Effectiveness in Health Insurance CoverageMichael Bertaut,Healthcare Economist Louisiana Blue 37 million Americans(out of 335 million people,roughly 11%of us)have Type 2 diabetes.Type 2 represents 95%of all diagnosed diabetes cases.In Louisiana the numb

2、er is higher,14.5%(505,000 people).85%of Type 2 diabetics were obese when diagnosed(BMI 30+).About 38%of Louisianas population is BMI 30+About 30%of BCBSLAs covered lives are BMI 30 or higher3*Multiple studies used from 2016-2022 sourced from Harvard Medical,US CDC,US NIH,the American Diabetes Assoc

3、iation and the American Hospital AssociationPopulation Health Type 2 Diabetic Statistics The actual progression of an obese population to Type-2 Diabetes(A1C 7%or higher)is not well understood and very difficult to predict on a case-by-case basis.0.9%of the adult BMI 30+population present with Type-

4、2 Diabetes in an average year(2022,9 per 1,000 obese)Up to age 33,the conversion rate is 0.3%(3 per 1,000)Estimates of the incremental direct healthcare costs of Type 2 diabetics(over non-obese,non-diabetic folks at the same age)range from$495 pmpm to$1,105 pmpm in extra costs.*Estimates of the all-

5、in incremental costs of non-diabetic obesity range from$149 pmpm to$254 pmpm.4*Multiple studies used from 2016-2022 sourced from Harvard Medical,US CDC,US NIH,the American Diabetes Association and the American Hospital AssociationLesser-Known Stats About Type 2 Diabetes and Non-Diabetic ObesityFinan

6、cial Simulation#1:GLP-1 Coverage for Type 2 Diabetes(36 Month Simulation)Model ParametersEmployer ModelCarrier ModelCovered Lives(Members)3,000500,000Type 2 Diabetics42672,500Total 3 Year Medical Spend w/o GLP-1$38 Million$6.3 BillionExpected 3 Year Drug Spend w/o GLP-1$9.5 Million$1.575 BillionGLP-